Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 43

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 43
---
nur to compete effectively in a highly competitive market; |

| • |     | the competition from larger pharmaceutical companies that have greater resources, technology, relationships and/or expertise; |

| • |     | the ability to protect and enhance Semnur’s corporate reputation and brand; |

| • |     | the impact from future regulatory, judicial, and legislative changes in Semnur’s industry; |

| • |     | Semnur’s and New Semnur’s ability to obtain and maintain regulatory approval of any of its product candidates; |

| • |     | Semnur’s and New Semnur’s ability to research, discover and develop additional product candidates; |

| • |     | Semnur’s and New Semnur’s ability to grow and manage growth profitably; |

| • |     | Semnur’s and New Semnur’s ability to obtain and maintain intellectual property protection and not infringe on the rights of others; |

| • |     | Semnur’s ability to execute its business plans and strategy; |

| • |     | Denali’s officers and directors allocating their time to other business and potentially having conflicts of interest with Denali’s business or in approving the Business Combination; |

| • |     | those factors set forth in documents of Denali filed, or to be filed, with SEC; and |

| • |     | other factors detailed under the section titled “Risk Factors.” |

Should one or more of these risks or uncertainties materialize or should any of the assumptions made by the management of Denali and Semnur prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. All subsequent written and oral forward-looking statements concerning the Business Combination or other matters addressed in this proxy statement/prospectus and attributable to Denali, Semnur or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this proxy statement/prospectus. Except to the extent required by applicable law or regulation, Denali and Semnur undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this proxy statement/prospectus or to reflect the occurrence of unanticipated events. 7

QUESTIONS AND ANSWERS ABOUT THE BUSINESS COMBINATION AND THE MEETING The following are answers to some questions that you, as a shareholder of Denali, may have regarding the Business Combination and the Meeting. We urge you to read carefully the remainder of this proxy statement